Four centres of excellence, 3,930 publications, 134 patents, and ₹6.24 Cr+ in active funding — driving breakthroughs across medicine, pharmacy, engineering, and natural sciences.
Shimadzu UV-2600i, Waters HPLC, Carl Zeiss microscopy — CRI houses state-of-the-art analytical infrastructure powering cross-disciplinary research.
AIMM's breakthroughs — US Patent Arishinin, SCID diagnostics, PID-15, and the 14kDa turmeric protein (UniProt P85278) — are reshaping molecular medicine.
CORBEVAX trials (₹72L), Ministry of Textiles (₹46.59L), VGST, KSCST, ICMR — funding breakthroughs across government and industry partnerships.
CMPAT & CORMIL bridge basic research and industry — with molecular pharmaceutics, advanced therapeutics, and international MoU partnerships driving real-world impact.
Full-time and part-time Ph.D programs across 8 faculties with ₹25K–40K/month fellowships. JRF, faculty grants, and 40+ research areas to choose from.
A comprehensive snapshot of ACU's research ecosystem — publications, patents, funding, and global partnerships driving innovation across eight faculties.
Four specialized centres driving breakthrough research across molecular medicine, drug discovery, industrial linkage, and core scientific instrumentation.
Houses Shimadzu UV-2600i spectrophotometer, Waters HPLC, Carl Zeiss microscope, and 37+ world-class instruments powering cross-disciplinary discovery.
Home to Arishinin drug discovery (US Patent 8,389,677B2), SCID, PID-15, and the 14kDa turmeric protein. 27+ specialized instruments including Tecan Freedom EVO 150.
Bridging basic research and real-world drug development — leveraging molecular biology, pharmacology, and advanced delivery systems to create therapeutic agents.
Facilitating research partnerships, navigating funding, and managing IP with Biovis PSA 2000, Anton Paar instruments, and industry collaboration frameworks.
Navigate across ten specialized areas — from publications and patents to molecular medicine and PhD regulations.
3,930 research articles published in Scopus, PubMed, Web of Science and UGC care Indexed Journals
→134 patents filed, 20 granted in pharma, biotech & engineering
→Govt & industry-funded projects worth ₹6.24 Cr+
→37+ world-class instruments & shared facilities
→Industrial linkage & molecular therapeutics
→Genetic analysis, protein research & drug discovery
→CPCSEA-registered pre-clinical research facility
→Admission, supervisor & thesis requirements
→38 active research partnerships across academia & industry
→Faculty & student research commendations
→Landmark discoveries from AIMM that are reshaping our understanding of molecular medicine and drug development.
A novel anti-inflammatory compound discovered at AIMM, granted a United States patent — representing ACU's first international drug discovery breakthrough.
AIMM's molecular diagnostics identified and characterized SCID cases, contributing to early diagnosis and treatment protocols for this rare genetic disorder.
Identification of PID-15, a primary immunodeficiency variant, advancing the understanding of immune system genetic disorders through molecular analysis.
Isolation and characterization of a novel 14kDa protein from turmeric, now registered in the UniProt international protein database — a first for an Indian university.
ACU research is powered by government agencies, industry partners, and internal seed grants — with over ₹6.24 Crore in active research funding.
Immuno-modulatory effects of Chitosan Nanoparticles from Bombyx mori
Development of encapsulation formulation for insulin-secreting artificial spheroids
State science & technology grants (Wnt-β catenin / mRNA delivery / antidiabetic adjuvant)
Civil, CSE, ECE, ISE student projects
Short-term studentship awards in medical research
CORBEVAX — COVID-19 vaccine Phase II/III clinical trial
Bioequivalence study of Paliperidone Palmitate (3-month) in adult schizophrenia
Cissus on weight & body-fat reduction in overweight/obese individuals — RCT
Safety profile of Streptococcus Salivarius UBSS-01 in healthy individuals
Livogen Phase IV — iron deficiency anemia post-marketing study (Liberty)
HRPT-091514 as adjuvant to standard of care in chronic kidney disease
ACU's internal seed grant program empowers faculty-led innovation by funding early-stage research projects across all constituent institutes.
The seed money program supports early-stage research across disciplines — from molecular biology and pharmacology to engineering and humanities. Faculty researchers receive funding to develop proof-of-concept studies that can attract larger external grants.
Seed Grant 2025-26 →Detailed project listings will be published shortly.
Faculty-wise project titles, principal investigators and detailed budget allocations for the 27 ACU Seed Money 2025 projects will be added here once the official sanction list is released by the Research & Innovation Council.
ACU's 38 active MoUs span industry and academia — from NIH-funded molecular medicine to CORBEVAX vaccine trials and partnerships with TCS, Dabur, and more.
Full-time and part-time doctoral programs across 8 faculties with 7 admission categories including JRF, faculty grants, and ACU employee pathways. Candidates require 3 first-author publications and 2 conference presentations, with a Q1/Q2 fast-track option for accelerated completion.
Dedicated councils ensuring quality, ethics, and strategic direction across all research activities.
18-member council chaired by Vice Chancellor Dr. S. N. Sridhara, providing strategic oversight of research direction, innovation policy, and cross-faculty coordination.
View Council →Reviews research proposals, monitors progress, and ensures academic rigour across departments.
View Committee →Ensures publication quality, ethics, and compliance with UGC-CARE and international standards.
View Guidelines →Access research policies, application forms, and institutional guidelines.
Explore doctoral programs, access world-class facilities, and contribute to discoveries that matter.